CompletedNot Applicable

Clinical Comparison of Treatment Strategies in AmpC Beta-lactamase Producing Enterobacterales in a Swiss Tertiary Care Hospital

Switzerland270 participantsStarted 2020-12-14

Plain-language summary

This study is to investigate the recent epidemiological trends and the treatment outcome in terms of the length of hospital stay, the relevant renal and neurological side effects, risk factors for developing these side effects, the selection of more resistant pathogens under therapy as well as the incidence of Clostridium difficile infections under treatment.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. In a blood culture (any ward)
✓. In a clinical sample of the lower respiratory tract (only intensive care unit)

What they're measuring

descriptive analyses of demographic data in patients with detection of AmpC beta-lactamase producing Enterobacterales

Timeframe: single time-point at baseline

descriptive analyses of clinical data in patients with detection of AmpC beta-lactamase producing Enterobacterales

Timeframe: single time-point at baseline

descriptive analyses of treatment data in patients with detection of AmpC beta-lactamase producing Enterobacterales

Timeframe: single time-point at baseline

descriptive analyses of microbiological data in patients with detection of AmpC beta-lactamase producing Enterobacterales

Timeframe: single time-point at baseline

Trial details

NCT IDNCT04577989

SponsorUniversity Hospital, Basel, Switzerland

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2022-12-19

View on ClinicalTrials.gov More Infection With AmpC Beta-lactamase Producing Enterobacterales trials